Lancet Rheumatology

Papers
(The H4-Index of Lancet Rheumatology is 41. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-02-01 to 2025-02-01.)
ArticleCitations
Composite endpoints for Sjögren's Syndrome387
Is it Autumn for colchicine and osteoarthritis?283
Cardiovascular risk in gout: time for action233
Thank you to The Lancet Rheumatology's peer reviewers in 2023217
FDA approval for anifrolumab in patients with lupus178
Withholding methotrexate after vaccination with ChAdOx1 nCov19 in patients with rheumatoid or psoriatic arthritis in India (MIVAC I and II): results of two, parallel, assessor-masked, randomised contr144
Pausing drugs and spacing vaccines: an open question134
Performance of large language models in rheumatology board-like questions: accuracy, quality, and safety132
The inclusion of Indigenous voices in health research131
Integrating evidence from lived experience of Aboriginal people and clinical practice guidelines to develop arthritis educational resources: a mixed-methods study126
Rheumatic cognitive impairment: a new clinical entity?126
CD19-targeting CAR T-cell therapy in patients with diffuse systemic sclerosis: a case series118
Immunoglobulin, glucocorticoid, or combined therapy for multisystem inflammatory syndrome in children102
How should we define disease and outcomes in axial psoriatic arthritis?102
Brachial plexopathy: an unusual manifestation of Takayasu arteritis101
Post-COVID condition in patients with inflammatory rheumatic diseases: a prospective cohort study in the Netherlands99
Women in rheumatology in Africa93
Research in Brief84
Toxic epidermal necrosis-like acute cutaneous lupus erythematosus83
Getting serious about sex and gender74
Novel COVID-19 therapies: the road ahead for rheumatology74
1-year results of treatment with rituximab in polymyalgia rheumatica: an extension study of a randomised double-blind placebo-controlled trial72
Unravelling extracellular matrix biomarkers in systemic sclerosis68
Brett Thombs: an unconventional journey66
Research in Brief65
Monoclonal gammopathy of clinical significance: what the rheumatologist needs to know64
Research in Brief62
National differences in vaccine hesitancy: a concern for the external validity of vaccine studies61
The role of skin ultrasound in systemic sclerosis: looking below the surface to understand disease evolution61
Cervical spinal gout57
Correction to Lancet Rheumatol 2020; 2: e557–6456
Research in Brief55
Long-awaited action on rare diseases54
Pandemic to endemic: optimising COVID-19 immunity53
Can contextual factors improve clarity of the results from clinical trials of low back pain?49
Composite of Relevant Endpoints for Sjögren's Syndrome (CRESS): development and validation of a novel outcome measure45
Patient–researcher co-presentation of research results to people living with systemic sclerosis45
Industry involvement in rheumatology consensus-based recommendations: a systematic review43
Survivorship of revised and multiply revised knee replacements41
Research in Brief41
Changing COVID-19 outcomes in patients with rheumatic disease—are we really getting better at this?41
0.11785006523132